Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-137109

Published: 2020

Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Peter M. Voorhees, Cesar Rodriguez, MD, Brandi Reeves, MD, Nitya Nathwani, MD, Luciano J. Costa, MD PhD, Yana Lutska, PharmD, Padma Bobba, Daniela Hoehn, Huiling Pei, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137105

Published: 2020

Journal Articles

Use of Anti-Infective Prophylaxis in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Initiating Treatment with Daratumumab

Ming-Hui Tai, PhD, Eric M. Ammann, PhD, Shuchita Kaila, PhD, Christopher Pericone, Ajaybir Singh, Thomas S. Lin, MD PhD, Faith E. Davies

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-134086

Published: 2020

Journal Articles

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Blood (2019) 134 (Supplement_1): 691.

https://doi.org/10.1182/blood-2019-123465

Published: 2019

Journal Articles

Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study

Nina D. Shah, MD, Yana Lutska, PharmD, Huiling Pei, PhD, Ming Qi, MD PhD, Maria Krevvata, PhD, Colleen Kane, PhD VMD, Jon Ukropec, PhD, Thomas S. Lin, MD PhD, Shalaka Hampras, MBBS, PhD MPH

Blood (2019) 134 (Supplement_1): 1829.

https://doi.org/10.1182/blood-2019-122471

Published: 2019

Journal Articles

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Robert M. Rifkin, MD, Jason M. Melear, MD, Edward Faber, DO, MS, William I. Bensinger, John M Burke, MD, Mohit Narang, MD, Don Stevens, MD, Sriya Gunawardena, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas S. Lin, MD PhD, Habte A Yimer, MD

Blood (2019) 134 (Supplement_1): 863.

https://doi.org/10.1182/blood-2019-122497

Published: 2019

Journal Articles

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

Daphne Guinn, Amy S. Ruppert, MAS, Kami J. Maddocks, MD, Samantha Jaglowski, MD MPH, Amber L. Gordon, Thomas S. Lin, MD PhD, Richard A. Larson, Guido Marcucci, MD, Erin K Hertlein, PhD, Jennifer A. Woyach, MD, Amy J. Johnson, PhD, John C. Byrd, MD

Blood (2014) 124 (21): 3297.

https://doi.org/10.1182/blood.V124.21.3297.3297

Published: 2014

Journal Articles

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Gustaaf W van Imhoff, MD PhD, Andrew McMillan, Matthew J. Matasar, MD MS, John Radford, MD FRCP, Kirit M Ardeshna, MD FRCPath, Kazimierz Kuliczkowski, WonSeog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, MD PhD, Michael Fennessy, PhD, Qiming Liao, PhD, Bronno van der Holt, PhD, Steen Lisby, Thomas S. Lin, MD PhD, Anton Hagenbeek, MD PhD

Blood (2014) 124 (21): 630.

https://doi.org/10.1182/blood.V124.21.630.630

Published: 2014

Journal Articles

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

Myron S. Czuczman, MD, Georg Hess, Ole Gadeberg, Lars Moeller Pedersen, Per Hansen, David Belada, M.D., Ph.D., Stephanie A. Gregory, MD, Brad Pohlman, MD, Jiri Mayer, M.D., PhD., Prof., Robert Pytlik, Lorenz Trumper, Andreas Viardot, MD, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Paul Winter, Nancy Goldstein, Roxanne C. Jewell, PhD, Steen Lisby, MD, DMSc

Blood (2012) 120 (21): 1632.

https://doi.org/10.1182/blood.V120.21.1632.1632

Published: 2012

Journal Articles

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

Richard R. Furman, MD, Herbert Eradat, MD, MS, Christine Gabriella DiRienzo, BS, PhD, Suzanne R Hayman, MD, Craig C. Hofmeister, MD, Nathalie A. Avignon, BA, John P. Leonard, MD, Morton Coleman, MD, Ranjana Advani, MD, Julie C. Switzky, RN, MSN, MBA, Qiming Liao, PhD, Damini N. Shah, Steen Lisby, MD, DMSc, Thomas S Lin, MD, PhD

Blood (2011) 118 (21): 3701.

https://doi.org/10.1182/blood.V118.21.3701.3701

Published: 2011

Journal Articles

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Jennifer A. Woyach, MD, Amy S. Ruppert, MAS, Bercedis Peterson, PhD, MS, Kanti R. Rai, M.D., Thomas S. Lin, MD, PhD, Frederick R. Appelbaum, MD, Martin S. Tallman, MD, Andrew R Belch, MD, Richard A. Larson, MD, John C. Byrd, MD

Blood (2011) 118 (21): 289.

https://doi.org/10.1182/blood.V118.21.289.289

Published: 2011

Journal Articles

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.

Jeffrey A. Jones, MD, MPH, Amy Stark, MAS, Weiqiang Zhao, MD PhD, Thomas S. Lin, MD, PhD, Kanti R Rai, MD, Guido Marcucci, MD, Bercedis Peterson, PhD, MS, Richard A. Larson, MD, Nyla A. Heerema, PhD, John C. Byrd, MD

Blood (2011) 118 (21): 1791.

https://doi.org/10.1182/blood.V118.21.1791.1791

Published: 2011

Journal Articles

Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study

Bertrand Coiffier, MD, PhD, André Bosly, MD, Ka Lung Wu, MD, PhD, Gregor Verhoef, MD, PhD, Van Eygen Koen, MD, Giovanni Martinelli, MD, Gabriela Barca, MD, PhD, Andrew Davies, MRCP, PhD, Eve Gallop-Evans, PhD, Swaminathan Padmanabhan, MBBS, MS, Ira V. Gupta, MD, Thomas S. Lin, MD, PhD, Randy L. Davis, DrPH, Nedjad Losic, MSC, Steen Lisby, MD, DMSC, John A. Radford, MD

Blood (2010) 116 (21): 3955.

https://doi.org/10.1182/blood.V116.21.3955.3955

Published: 2010

Journal Articles

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Mark S. Kaminski, MD, Andrew D. Zelenetz, MD, Oliver W. Press, MD, PhD, Mansoor N. Saleh, MD, John P. Leonard, MD, Louis Fehrenbacher, MD, T. Andrew Lister, MD, Thierry J. Horner, PhD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Christina Vleisides, DC, Susan J. Knox, MD, PhD, Richard L. Wahl, MD, Julie M. Vose

Blood (2010) 116 (21): 3960.

https://doi.org/10.1182/blood.V116.21.3960.3960

Published: 2010

Journal Articles

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

Thierry J. Horner, PhD, Jeffry A. Siegel, MS, MS, PhD, Roxanne C. Jewell, PhD, Gary J. Lunger, MSRIS, RT(R)(N)ARRT, Nancy L. Young, BS, NMT, Brian R. Wynne, MD, Vanessa C. Williams, MS, Thomas S. Lin, MD, PhD, Mark S. Kaminski, MD, Richard L. Wahl, MD, Christina Vleisides, DC

Blood (2010) 116 (21): 4916.

https://doi.org/10.1182/blood.V116.21.4916.4916

Published: 2010

Journal Articles

A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.

Richard R. Furman, MD, Herbert Eradat, MD, MS, Julie C. Switzky, RN, MSN, MBA, Suzanne R. Hayman, MD, Craig C. Hofmeister, MD, Nathalie A. Avignon, BA, John P. Leonard, MD, Morton Coleman, MD, Qiming Liao, PhD, Damini N. Shah, Stephanie Brownell-Buttich, BFA, Steen Lisby, MD, DMSC, Thomas S. Lin, MD, PhD

Blood (2010) 116 (21): 1795.

https://doi.org/10.1182/blood.V116.21.1795.1795

Published: 2010

Journal Articles

Conditioning with Fludarabine, Busulfan, and ATG Prior to Reduced-Intensity Allogeneic Stem Cell Transplant for CLL Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease.

Samantha M. Jaglowski, MD, Diane Scholl, Patrick Elder, MS, Thomas S. Lin, MD, PhD, John C. Byrd, MD, Steven M. Devine, MD, Leslie Andritsos, MD

Blood (2010) 116 (21): 4568.

https://doi.org/10.1182/blood.V116.21.4568.4568

Published: 2010

Journal Articles

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

Samantha M. Jaglowski, MD, Joseph M. Flynn, DO, MPH, Jeffrey A. Jones, MD, MPH, Thomas S. Lin, MD, PhD, Beth Fischer, Diane Scholl, Patrick Elder, MS, Steven M. Devine, MD, Michael R. Grever, M.D., John C. Byrd, MD, Leslie Andritsos, MD

Blood (2010) 116 (21): 2383.

https://doi.org/10.1182/blood.V116.21.2383.2383

Published: 2010

Journal Articles

Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease.

Jennifer A Woyach, MD, John C. Byrd, MD, John Zhao, MD, PhD, Andrew McFaddin, Amy S Ruppert, Thomas S Lin, MD, PhD, Leslie Andritsos, MD, Kristie A Blum, MD, Joseph M Flynn, DO, MPH, Jeffrey Alan Jones, MD, MPH, Nyla A. Heerema, PhD

Blood (2009) 114 (22): 1233.

https://doi.org/10.1182/blood.V114.22.1233.1233

Published: 2009

Journal Articles

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101.

Thomas S Lin, MD, PhD, Kathleen A Donohue, John C. Byrd, MD, Margaret S Lucas, Eva Hoke, Elizabeth M Bengtson, MD, James N Atkins, MD, Brian K Link, MD, Kanti R Rai, MD, Richard A Larson, MD

Blood (2009) 114 (22): 210.

https://doi.org/10.1182/blood.V114.22.210.210

Published: 2009

NARROW

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of Griffin

Use of Anti-Infective Prophylaxis in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients Initiating Treatment with Daratumumab

Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update

Daratumumab (DARA) Plus Lenalidomide Versus Lenalidomide Alone As Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma (NDMM) after Frontline Autologous Stem Cell Transplant (ASCT): Use of Minimal Residual Disease (MRD) As a Novel Primary Endpoint in the Phase 3 Auriga Study

Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study

Mir-155 Expression Is Associated with Chemoimmunotherapy Outcome and Is Modulated By Bruton’s Tyrosine Kinase Inhibition with Ibrutinib

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928)

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,

Impact of Age on Outcomes Following Initial Therapy with Various Chemotherapy and Chemoimmunotherapy Regimens in Patients with Chronic Lymphocytic Leukemia (CLL): Results of CALGB Studies

Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials.

Ofatumumab Monotherapy for Treatment of Patients with Relapsed/Progressive Diffuse Large B-Cell Lymphoma: Results From a Multicenter Phase II Study

Tositumomab and I 131 Tositumomab Achieves Complete Remissions Lasting > 10 Years In Patients with Chemotherapy-Refractory Low-Grade and Transformed B-Cell Lymphomas

Comparison of Dosimetry and Gamma Camera Methods for Evaluation of Biodistribution Prior to Administration of the Therapeutic Dose of Tositumomab and Iodine I 131 Tositumomab (Bexxar Therapeutic Regimen)

A Phase II Trial of Ofatumumab In Subjects with Waldenstrom's Macroglobulinemia.

Conditioning with Fludarabine, Busulfan, and ATG Prior to Reduced-Intensity Allogeneic Stem Cell Transplant for CLL Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease.

Flavopiridol Is An Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant

Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only